Taken together, based on our results, we propose a hypothesis that SGK3, a serum glucocorticoid kinase, is upregulated in alpelisib-resistant breast cancer cells and activates GSK3β/β-catenin signaling, which in turn promotes the stemness of breast cancer cells and ultimately promotes the resistance to alpelisib. This evidence concerns the gene GSK3B and breast carcinoma.